加载中
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
常规交易时段
US$6.47
−US$0.24 · -3.58%
盘中时间采用ET。市场数据可能有所延迟。
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
日内区间
当前US$6.47
52周区间
当前US$6.47
盘中时间采用ET。市场数据可能有所延迟。
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
日内区间
当前US$6.47
52周区间
当前US$6.47
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 809.4万 USD | 1362万 USD |
| 销货成本 | 163.6万 USD | 245.5万 USD | 258.1万 USD | — | — |
| 毛利 | −163.6万 USD | −245.5万 USD | −258.1万 USD | 809.4万 USD | 1362万 USD |
| 研究与开发 | 1.4亿 USD | 9643.1万 USD | 7656.3万 USD | 7842万 USD | 5873.9万 USD |
| 销售、一般及管理费用 | 3888.1万 USD | 3329.7万 USD | 2775.2万 USD | 2894.8万 USD | 2713.5万 USD |
| 营业费用 | 1.78亿 USD | 1.27亿 USD | 1.02亿 USD | 1.15亿 USD | 8587.4万 USD |
| 利息收入 | 990.4万 USD | 946.9万 USD | 714.2万 USD | 261.6万 USD | 6.4万 USD |
| 利息支出 | — | 34万 USD | — | — | — |
| 折旧和摊销 | 163.6万 USD | 245.5万 USD | 258.1万 USD | 240.8万 USD | 296.4万 USD |
| 营业利润 | −1.79亿 USD | −1.3亿 USD | −1.04亿 USD | −1.06亿 USD | −7225.4万 USD |
| 净利润 | −1.74亿 USD | −1.25亿 USD | −9601.5万 USD | −8598.1万 USD | −7218.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$20.50
上涨空间 216.85%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2022年10月28日 | 1:15 | — | — |
已生效 2022年10月28日
1:15
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3016.34万0.00%2.3万亿 USD0.03%US$381.72+0.04%
iShares Russell 2000 ETFIWM1307.28万0.02%787.4亿 USD0.19%US$277.92+0.01%
State Street SPDR S&P Biotech ETFXBI1183.64万0.12%103.03亿 USD0.35%US$148.95-1.62%
Vanguard Extended Market ETFVXF750.79万0.01%954亿 USD0.05%US$233.56+0.02%
iShares Biotechnology ETFIBB448.53万0.04%108.2亿 USD0.44%US$201.87-1.17%
Vanguard Russell 2000 ETFVTWO432.81万0.02%180亿 USD0.06%US$112.26-0.01%
Dimensional - US Small Cap ETFDFAS431.3万0.01%338.04亿 USD0.31%US$78.39+0.28%
Fidelity Enhanced Small Cap ETFFESM355.2万0.05%64.1亿 USD0.28%US$45.27+0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
